111, Inc. · NASDAQ:YI
111 — Q4 2024 Earnings Presentation
27 slides from 111's earnings presentation, Mar 20, 2025
Slide 1: 111, Inc. Fourth Quarter and Fiscal Year 2024 Earnings Call
111, Inc. (NASDAQ: YI) Reshaping the Value Chain of Healthcare Industry with Digital Technology Fourth Quarter and Fiscal Year 2024 Earnings Call March 20, 2025 1
Slide 2: Disclaimer
DISCLAIMER The following presentation has been prepared by 111,. Inc. (“111” or the “Company”) solely for informational purposes and Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ should not be construed to be, directl
Slide 3: Content
1 BUSINESS & OPERATIONAL PERFORMANCE HIGHLIGHTS 2 FINANCIAL REVIEW 3CONTENT APPENDIX 3
Slide 4: Resilience in Action: First-Ever Annual Operating Profit
Resilience in Action: Achieving First-Ever Annual Operational Profit Amid Macroeconomic Challenges First-Ever -470bps -230bps Annual YoY YoY Operating Profit Q4’24 Operating 2024 Operating and Positive Expense as a Expense as a Operating Cash Percentage of Percentage of Flow Revenues Revenues Macroe
Slide 5: Resilient Revenue Performance and Gross Margin Growth Amid Macroeconomic Challenges
Resilient Revenue Performance and Gross Margin Growth Amid Macroeconomic Challenges Revenue – Total Gross Segment Margin – Total 1 (Million) (Million) YoY -5.5% YoY -2.3% YoY -6.3% YoY -3.7% 5.2% 5.3% 5.7% 5.8% RMB14,948 USD2,105 RMB849 RMB829 RMB14,401 USD120 USD114 USD1,973 RMB4,109 RMB3,848 USD57
Slide 6: Driving Operational Excellence
Driving Operational Excellence (Excluding Share-Based Compensation Expenses) Selling and Marketing Expense Fulfillment Expense as % of Net Revenue Workforce as % of Net Revenue Optimization YoY -70bps YoY -40bps YoY +20bps YoY -10bps 2.6% 2.5% 2.7% 2.7% 2.6% 2.5% 2.1% Streamlined 1.9% Management Imp
Slide 7: Achieved First-Ever Annual Operational Profitability Through Enhanced Efficiency
Achieved First-Ever Annual Operational Profitability Through Enhanced Efficiency Operating Expense as % of Net Revenue (Excluding Share-Based Compensation Expenses) Excluding Share-Based Excluding Share-Based YoY -130bps YoY -90bps Compensation Expenses Compensation Expenses 2023 Q4 2024 Q4 2023 202
Slide 8: Reshaping Entire Value Chain of Healthcare Industry with Digital Technology
Reshaping Entire Value Chain of Healthcare Industry with Digital Technology Digital Model Industry Upgrade Traditional Model De-Intermediation of Pharmas Data Direct Linkage & Digital Enablement Industrial Supply Chain Pharmas Transaction Automation Primary Distributor 111, Inc. Intelligent Se
Slide 9: Driving Operational Excellence by Leveraging Technology
Driving Operational Excellence by Leveraging Technology Customer Acquisition & Retention Expense Control Supply Chain Support Resource Utilization Market Expansion Operating Expenditure Ratio1 (Excluding Share-Based Compensation Expenses) YoY -130 bps Technology 6.6% 5.3% 4Q23 4Q24 Note: 1. The rati
Slide 10: Technology Empowerment: Optimizing Supply, Driving Demand, and Enhancing AI Development
Technology Empowerment: Optimizing Supply, Driving Demand, and Enhancing AI Development Supply Empowerment Demand Stimulation Enhanced AI-Powered Demand Analysis Through the JBP Platform and Inventory Sharing During flash sales event from November to December, we used Combined with company and
Slide 11: Kunpeng Pharmaceutical Logistics Network Fuels Supply Chain Cost Reduction
Kunpeng Pharmaceutical Logistics Network Fuels Supply Chain Cost Reduction Our goal is to establish a national pharmaceutical logistics network, ensuring efficient last-mile delivery in supply- dense areas while maintaining full control of the supply chain. 5 Super Hubs Major fulfillment centers for
Slide 12: Operational Excellence: Enhancing Supply Chain Efficiency with Reduced Costs
Operational Excellence: Enhancing Supply Chain Efficiency with Reduced Costs Logistics Expenses -4.9% YoY 2.7% YoY – 10bps 2.6% Fulfillment Expenses Dropped by RMB20 million to RMB381 million in 2024 from RMB401 million a year ago. -10bps YoY -RMB20 mln Fulfillment Expenses as a Percentage of Revenu
Slide 13: Nationwide Fulfillment Network Expansion Strengthens Supply and Distribution
Nationwide Fulfillment Network Expansion Strengthens Supply and Distribution Capabilities 111 National Fulfillment Network Significant Progress and New Goal 7 Q4’24 New Fulfillment Centers They were added in Guangzhou, Wuhan, Shijiazhuang, Ji’nan, Chongqing, Xinjiang and Hunan 18 Total Fulfillment C
Slide 14: Leading the Way: Discover Our Latest Accolades
Leading the Way: Discover Our Latest Accolades 3 Awards: “Most Valuable Healthcare and Pharmaceutical Company for Investment”, “Top 100 Private Enterprises” in Chongqing, and “Outstanding Case of Productive Internet Service Platform” in Shanghai’s Pudong New Area underscore our strong business perfo
Slide 15: Shaping the Future: Enhancing Leadership and Competitive Advantage
Shaping the Future: Enhancing Leadership and Competitive Advantage with a Structured Approach Digitization Supply Side Pledging to digital transformation Empowerment Helping pharmaceutical companies curate their Efficiency product offerings and expand their reach through Focusing on operational our
Slide 16: Unlocking Success: Relentlessly Driving Revenue and Margin Growth
Unlocking Success: Relentlessly Driving Revenue and Margin Growth Tech-Enabled Healthcare Platform to Revolutionize Healthcare Value Chain Optimizing AI Innovations and Operational Costs Strengthened Supply Digitalization Best Selection and Stimulating Demand & • Adopting the transshipment Customer
Slide 17: Content
1 BUSINESS & OPERATIONAL PERFORMANCE HIGHLIGHTS 2 FINANCIAL REVIEW 3CONTENT APPENDIX 17
Slide 18: Total Revenue Holds Firm Despite Macroeconomic Challenges
Total Revenue Holds Firm Despite Macroeconomic Challenges Revenue – Total B2B Segment 1 – Revenue (Million) YoY -6.3% YoY -3.7% (Million) YoY -5.9% YoY -3.1% RMB14,571 RMB14,123 RMB14,948 USD2,052 USD1,935 USD2,105 RMB4,021 RMB3,782 RMB14,401 USD1,973 USD567 USD518 RMB4,109 RMB3,848 2023 Q4 2024 Q4
Slide 19: Gross Margin Growth Amid Macroeconomic Challenges
Gross Margin Growth Amid Macroeconomic Challenges Gross Segment Margin – Total 1 B2B Segment 2 – Gross Segment Margin (Million) (Million) 4.9% 5.3% 5.4% 5.0% 5.7% 5.8% RMB849 RMB829 RMB770 YoY -0.5% RMB765 USD120 YoY -2.3% USD109 USD105 USD114 RMB199 YoY -5.0% RMB189 USD28 USD26 5.2% 5.3% RMB214 RMB
Slide 20: Achieved First-Ever Annual Operational Profitability Through Enhanced Efficiency
Achieved First-Ever Annual Operational Profitability Through Enhanced Efficiency Operating Expense as % of Net Revenue (Excluding Share-Based Compensation Expenses) Excluding Share-Based Excluding Share-Based YoY -130bps YoY -90bps Compensation Expenses Compensation Expenses 2023 Q4 2024 Q4 2023 202
Slide 21: Content
1 BUSINESS & OPERATIONAL PERFORMANCE HIGHLIGHTS 2 FINANCIAL REVIEW 3CONTENT APPENDIX 21
Slide 22: Selected Balance Sheet Summary
Selected Balance Sheet Summary As of December 31, 2023 December 31, 2024 '000 RMB USD RMB USD Cash and cash equivalents, restrict cash and short-term 673,691 94,886 518,332 71,011 investments Total current assets 2,933,331 413,150 2,649,657 363,001 Total assets 3,089,036 435,083 2,787,750 381,920 To
Slide 23: Selected Income Statement Summary
Selected Income Statement Summary For the Three Months Ended For the Year Ended December 31, 2023 December 31, 2024 December 31, 2023 December 31, 2024 '000 RMB USD RMB USD RMB USD RMB USD Net revenues 4,108,626 578,689 3,847,775 527,143 14,948,129 2,105,399 14,401,249 1,972,963 Cost of products sol
Slide 24: Cash Flow Statements
Cash Flow Statements For the Three Months Ended For the Year Ended December 31, 2023 December 31, 2024 December 31, 2023 December 31, 2024 '000 RMB USD RMB USD RMB USD RMB USD Net cash (used in) provided by operating activities (197,014) (27,749) (48,547) (6,652) (447,244) (62,993) 263,016 36,033 Ne
Slide 25: Non-GAAP Financial Measures Reconciliation
Non-GAAP Financial Measures Reconciliation For the Three Months Ended For the Year Ended December 31, 2023 December 31, 2024 December 31, 2023 December 31, 2024 '000 RMB USD RMB USD RMB USD RMB USD (Loss)/Income from operations (206,538) (29,089) (7,319) (1,003) (350,097) (49,311) 2,114 289 Add: Sha
Slide 26: Q&A
Q&A MHtine. | 1am
Slide 27: Thank You
THANK YOU MHtine. | 1am